相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition
Wook Jin
CELLS (2020)
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
Shaokun Shu et al.
MOLECULAR CELL (2020)
STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects
Milad Ashrafizadeh et al.
BIOLOGY-BASEL (2020)
Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms
Linfeng Gao et al.
NATURE COMMUNICATIONS (2020)
BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway
Guangtong Deng et al.
THERANOSTICS (2020)
Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4
Padmaja Wakchaure et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
Stat3 activation is critical for pluripotency maintenance
Yan Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations
Amos H. P. Loh et al.
CANCER LETTERS (2019)
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma
Gangyang Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer
Sofia Genta et al.
CURRENT ONCOLOGY REPORTS (2019)
Genome-Informed Targeted Therapy for Osteosarcoma
Leanne C. Sayles et al.
CANCER DISCOVERY (2019)
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Jo Lynne Rokita et al.
CELL REPORTS (2019)
Attenuation of STAT3 Phosphorylation Promotes Apoptosis and Chemosensitivity in Human Osteosarcoma Induced by Raddeanin A
Zhuoying Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis
Yafei Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Coactivator condensation at super-enhancers links phase separation and gene control
Benjamin R. Sabari et al.
SCIENCE (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways
Dongqing Zuo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
Xiangpeng Dai et al.
NATURE MEDICINE (2017)
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
Pingzhao Zhang et al.
NATURE MEDICINE (2017)
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
T. Zhang et al.
ONCOGENE (2017)
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Kuisheng Liu et al.
CELL DEATH & DISEASE (2017)
Monocytes, Macrophages, and Osteoclasts in Osteosarcoma
Fergal C. Kelleher et al.
JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY (2017)
Stat3 promotes mitochondrial transcription and oxidative respiration during maintenance and induction of naive pluripotency
Elena Carbognin et al.
EMBO JOURNAL (2016)
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Cristina Meazza et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Henry E. Pelish et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
The Great Beauty of the osteoclast
Alfredo Cappariello et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL
Tetsuro Ohba et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Formulated siRNAs Targeting Rankl Prevent Osteolysis and Enhance Chemotherapeutic Response in Osteosarcoma Models
Julie Rousseau et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Osteoblastic and Osteolytic Human Osteosarcomas can be Studied With a New Xenograft Mouse Model Producing Spontaneous Metastases
Jun Yuan et al.
CANCER INVESTIGATION (2009)
Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway
Toru Akiyama et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice
J Cao et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
分享论文
